S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:SMTI

Sanara MedTech Stock Forecast, Price & News

$26.79
-0.71 (-2.58%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$25.00
$28.40
50-Day Range
$26.79
$37.90
52-Week Range
$21.30
$53.85
Volume
22,107 shs
Average Volume
25,719 shs
Market Capitalization
$204.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.21
30 days | 90 days | 365 days | Advanced Chart
Receive SMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.


Sanara MedTech logo

About Sanara MedTech

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMTI
Fax
N/A
Employees
41
Year Founded
N/A

Sales & Book Value

Annual Sales
$15.59 million
Book Value
$0.93 per share

Profitability

Net Income
$-4.36 million
Pretax Margin
-18.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
3,112,000
Market Cap
$204.46 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/29/2022

MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

518th out of 1,388 stocks

Surgical Appliances & Supplies Industry

12th out of 27 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Sanara MedTech (NASDAQ:SMTI) Frequently Asked Questions

Is Sanara MedTech a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Sanara MedTech stock.
View analyst ratings for Sanara MedTech
or view top-rated stocks.

How has Sanara MedTech's stock price been impacted by Coronavirus?

Sanara MedTech's stock was trading at $11.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SMTI shares have increased by 138.1% and is now trading at $26.79.
View which stocks have been most impacted by COVID-19
.

When is Sanara MedTech's next earnings date?

Sanara MedTech is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Sanara MedTech
.

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.09. The firm earned $5.82 million during the quarter. Sanara MedTech had a negative trailing twelve-month return on equity of 18.38% and a negative net margin of 18.39%. During the same period in the previous year, the business posted ($0.18) earnings per share.
View Sanara MedTech's earnings history
.

What price target have analysts set for SMTI?

1 analysts have issued 1-year price targets for Sanara MedTech's shares. Their forecasts range from $45.00 to $45.00. On average, they expect Sanara MedTech's share price to reach $45.00 in the next year. This suggests a possible upside of 68.0% from the stock's current price.
View analysts' price targets for Sanara MedTech
or view top-rated stocks among Wall Street analysts.

Who are Sanara MedTech's key executives?

Sanara MedTech's management team includes the following people:
  • J. Michael Carmena, Vice Chairman & Chief Executive Officer
  • Zach Fleming, Co-Chief Operating Officer & VP-Surgical Division
  • Shawn M. Bowman, Co-Chief Operating Officer & President-Wound Care
  • Michael D. McNeil, Secretary, Chief Financial & Accounting Officer
  • Rebecca E. Mcmahon, President-Research & Development

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), Aurora Cannabis (ACB), AC Immune (ACIU) and Applied Genetic Technologies (AGTC).

What is Sanara MedTech's stock symbol?

Sanara MedTech trades on the NASDAQ under the ticker symbol "SMTI."

Who are Sanara MedTech's major shareholders?

Sanara MedTech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Laurion Capital Management LP (0.37%), New York State Common Retirement Fund (0.26%), Citadel Advisors LLC (0.08%), Rockefeller Capital Management L.P. (0.06%) and Morgan Stanley (0.06%). Company insiders that own Sanara MedTech stock include Shawn M Bowman and Zachary B Fleming.
View institutional ownership trends for Sanara MedTech
.

Which major investors are selling Sanara MedTech stock?

SMTI stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP. Company insiders that have sold Sanara MedTech company stock in the last year include Shawn M Bowman, and Zachary B Fleming.
View insider buying and selling activity for Sanara MedTech
or view top insider-selling stocks.

Which major investors are buying Sanara MedTech stock?

SMTI stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Citadel Advisors LLC, Morgan Stanley, and Rockefeller Capital Management L.P..
View insider buying and selling activity for Sanara MedTech
or or view top insider-buying stocks.

How do I buy shares of Sanara MedTech?

Shares of SMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sanara MedTech's stock price today?

One share of SMTI stock can currently be purchased for approximately $26.79.

How much money does Sanara MedTech make?

Sanara MedTech has a market capitalization of $204.46 million and generates $15.59 million in revenue each year. The company earns $-4.36 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Sanara MedTech have?

Sanara MedTech employs 41 workers across the globe.

What is Sanara MedTech's official website?

The official website for Sanara MedTech is www.wndm.com.

Where are Sanara MedTech's headquarters?

Sanara MedTech is headquartered at 1200 Summit Avenue Suite 414, Fort Worth TX, 76102.

How can I contact Sanara MedTech?

Sanara MedTech's mailing address is 1200 Summit Avenue Suite 414, Fort Worth TX, 76102. The company can be reached via phone at (817) 529-2300 or via email at [email protected].


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.